Eritel H Tablet contains a combination of Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg, indicated primarily for the management of hypertension. Telmisartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, which results in vasodilation and reduction of blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes diuresis by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, leading to decreased plasma volume and peripheral vascular resistance. The synergistic effect of these two agents provides enhanced antihypertensive efficacy compared to monotherapy. Eritel H is indicated for patients whose blood pressure is not adequately controlled with Telmisartan alone. It is essential to monitor electrolyte levels, renal function, and blood pressure regularly during therapy to mitigate potential adverse effects such as hypotension, electrolyte imbalance, and renal impairment. Contraindications include hypersensitivity to either component, anuria, and severe renal or hepatic impairment. Caution is advised in patients with diabetes, gout, or electrolyte disturbances. Eritel H should be administered under medical supervision, with dosage adjustments based on clinical response and tolerability.